Tri Locum Partners’s ALX Oncology ALXO Stock Holding History

Tri Locum Partners’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-39,226	Closed	-$3.38M	–	36
2020 Q4	$3.38M	Buy	+39,226	New	+$2.36M	1.23%	22

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tri Locum Partners's ALXO Position: Q1 2021 in Review

Tri Locum Partners sold out of ALX Oncology (ALXO) in Q1 2021, closing a stake of 39,226 shares — an estimated $3.38M sold.

Tri Locum Partners first reported a position in ALXO in Q4 2020 and held it in 1 quarter. The position peaked at $3.38M in Q4 2020. 93 funds tracked by Wall St. Rank hold ALXO as of Q1 2021.

Tri Locum Partners reported no remaining ALX Oncology position as of Q1 2021 after selling out during the quarter.
Tri Locum Partners sold 39,226 ALX Oncology shares in Q1 2021, an estimated $3.38M.
Tri Locum Partners first reported a position in ALX Oncology in Q4 2020 and held it in 1 quarter.
Tri Locum Partners's ALX Oncology position peaked at $3.38M in Q4 2020.
93 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2021.

Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.